Parkinson's drug side effect targeted by antioxidant NAC – but trial stalls
NCT ID NCT03146130
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether N-acetylcysteine (NAC), an antioxidant, could help reduce impulse control disorders caused by Parkinson's medications. Only 14 people with mild-to-moderate symptoms were enrolled before the trial was stopped early. The goal was to see if 10 weeks of NAC improved behavior scores compared to a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- N-acetylcysteine (NAC)
- What this could lead to
- If it worked, NAC could offer a way to ease impulse control problems caused by Parkinson's drugs, improving daily life for some patients.
- What could go wrong
- The trial was terminated early and very small (14 people), so results are not reliable. NAC may not work for this purpose, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMPULSE CONTROL DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Amiens Picardie
Amiens, Picardie, 80054, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gene mutation may amplify cognitive risks of brain stimulation in Parkinson's
- Can simple calf raises rewire muscle energy in Parkinson's?
- Which balance test best predicts falls in Parkinson's? a head-to-head comparison
- Brain scans reveal early clues to Parkinson's progression
- Could your own stem cells heal your brain? new trial tests it
- Brain zap study reveals emotional wiring in Parkinson's